Full-Time

Senior Affiliates Manager

Posted on 9/23/2025

Mochi Health

Mochi Health

Telehealth obesity treatment with FDA meds

Compensation Overview

$200k - $250k/yr

San Francisco, CA, USA

In Person

Category
Growth & Marketing (1)
Required Skills
Marketing
Data Analysis
Requirements
  • 5+ years of growth, affiliate, or marketing experience; bachelor’s degree or equivalent
  • Proven track record of driving growth and scaling user acquisition in consumer technology
  • Strong grasp of growth strategies, tactics, and cross-channel best practices
  • Skilled at managing projects, teams, and budgets in fast-paced environments
  • Excellent communicator and leader with an entrepreneurial, innovative approach
Responsibilities
  • Develop and implement strategies to support overall growth and business objectives
  • Identify and prioritize opportunities that can create meaningful impact, informed by data and experimentation
  • Oversee and refine processes across the full customer journey, from awareness to retention
  • Collaborate with internal teams to ensure alignment between growth efforts and broader company goals
  • Lead and mentor a team, encouraging a culture of experimentation and continuous improvement
  • Utilize a variety of channels and approaches to support acquisition and engagement
  • Monitor and optimize performance metrics to guide strategic decisions
  • Stay informed on broader industry developments and evolving best practices

Mochi Health provides telehealth obesity treatment with personalized care using FDA-approved medications. Patients join a subscription that includes medical consultations and prescribed therapies, with options for cost-effective compounded generics. It focuses on underserved groups such as the uninsured, people facing language or cultural barriers, and residents of rural areas to remove access barriers in care. The goal is to make effective obesity treatment accessible and affordable by bundling ongoing care with affordable medication options.

Company Size

N/A

Company Stage

Seed

Total Funding

$550K

Headquarters

San Francisco, California

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Insurance-based plans launched May 2025 expand access with dietitians.
  • Wegovy pill provides FDA-approved oral obesity treatment option.
  • Compounded semaglutide offers affordable appetite-curbing alternative.

What critics are saying

  • Eli Lilly sues Mochi for deceptive tirzepatide marketing in 2026.
  • Novo Nordisk litigates Mochi over compounded semaglutide adverse events.
  • FDA probes Mochi-affiliated pharmacies for contamination and violations.

What makes Mochi Health unique

  • Mochi Health offers pediatric obesity programs at $99/mo for family care.
  • Dynamic protocols include 100+ nutritionist meal plans and sleep content.
  • Unlimited 24/7 messaging enables rapid treatment plan adjustments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Commuter Benefits

Company News

HIT Consultant
May 27th, 2025
Mochi Health Launches Insurance-Based Plans, Expanding Access To Personalized Obesity Care With Behavioral Therapy

Mochi Health Launches Insurance-Based Plans, Expanding Access to Personalized Obesity Care with Behavioral Therapy. by Jasmine Pennic 05/27/2025 Leave a Comment. What You Should Know: – Mochi Health, a physician-guided obesity care program, announced the launch of its new insurance-based plans. – These expanded offerings are designed to provide more personalized treatment experiences for patients, placing a strong emphasis on comprehensive obesity care that spans all aspects of an individual’s health. – The new insurance-based plans are available as an optional upgrade to Mochi’s existing offerings. They provide patients with access to either brand-name or compounded weight loss medication prescriptions, alongside routine video consultations with both a physician and a registered dietitian.Addressing a Growing National Health ConcernThe launch comes at a time when nearly three-quarters of U.S. adults are classified as overweight or obese, and approximately one in eight Americans are reportedly using GLP-1 medications for weight loss, underscoring the significant demand for effective solutions. Mochi Health’s expanded offerings aim to meet this need by blending personalized care with comprehensive support, recognizing that effective treatment must be tailored to the individual.Expanding Access to Comprehensive, Personalized Weight Loss SolutionsMochi Health’s new plans aim to cater to the unique needs of each individual navigating their weight loss journey

GlobalData
Apr 23rd, 2025
Eli Lilly sues Mochi Health and others for 'deceptive' tirzepatide marketing

Eli Lilly sues Mochi Health and others for 'deceptive' tirzepatide marketing.

INACTIVE